Your browser is no longer supported. Please, upgrade your browser.
Settings
CNST [NASD]
Constellation Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.80 Insider Own1.67% Shs Outstand47.63M Perf Week-0.93%
Market Cap1.11B Forward P/E- EPS next Y-3.72 Insider Trans-6.56% Shs Float47.22M Perf Month-24.72%
Income-126.40M PEG- EPS next Q-0.79 Inst Own- Short Float13.94% Perf Quarter-24.87%
Sales- P/S- EPS this Y-37.30% Inst Trans3.26% Short Ratio14.45 Perf Half Y-0.27%
Book/sh8.62 P/B2.59 EPS next Y-10.70% ROA-27.20% Target Price- Perf Year-33.22%
Cash/sh8.43 P/C2.64 EPS next 5Y- ROE-30.80% 52W Range17.00 - 50.90 Perf YTD-22.60%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-56.21% Beta-
Dividend %- Quick Ratio14.00 Sales past 5Y- Gross Margin- 52W Low31.12% ATR1.63
Employees154 Current Ratio14.00 Sales Q/Q- Oper. Margin- RSI (14)37.70 Volatility6.53% 6.70%
OptionableYes Debt/Eq0.00 EPS Q/Q-189.90% Profit Margin- Rel Volume0.87 Prev Close23.29
ShortableYes LT Debt/Eq0.00 EarningsFeb 24 BMO Payout- Avg Volume455.34K Price22.29
Recom2.00 SMA20-7.32% SMA50-21.15% SMA200-15.59% Volume395,066 Change-4.29%
Jan-25-21Upgrade BMO Capital Markets Market Perform → Outperform $50
Sep-08-20Downgrade Oppenheimer Outperform → Perform
Jul-20-20Resumed Jefferies Buy
Jun-24-20Initiated JMP Securities Mkt Perform $36
May-07-20Reiterated H.C. Wainwright Buy $50 → $75
Feb-13-20Initiated SunTrust Buy $50
Feb-07-20Initiated Cowen Outperform
Jan-09-20Downgrade BMO Capital Markets Outperform → Market Perform $43 → $42
Sep-04-19Initiated RBC Capital Mkts Outperform $20
Jan-29-19Initiated Robert W. Baird Outperform $17
Dec-20-18Initiated H.C. Wainwright Buy $18
Dec-20-18Initiated H.C. Wainwright Buy
Aug-13-18Initiated JP Morgan Overweight $17
Apr-08-21 11:10AM  
Feb-26-21 12:40AM  
Feb-24-21 10:30PM  
07:00AM  
06:15AM  
Feb-19-21 04:00PM  
Feb-18-21 10:00AM  
Feb-16-21 01:27PM  
Jan-25-21 12:32PM  
Jan-07-21 09:30AM  
Jan-06-21 10:00AM  
Dec-07-20 04:20PM  
Dec-06-20 08:00AM  
Nov-23-20 01:00PM  
Nov-10-20 10:22AM  
Oct-29-20 07:00AM  
06:00AM  
Oct-19-20 02:00PM  
Sep-10-20 10:06AM  
Sep-09-20 03:00PM  
Sep-03-20 10:21AM  
Aug-05-20 07:00AM  
Aug-04-20 11:08AM  
Jul-31-20 12:00PM  
Jul-20-20 12:15PM  
Jul-15-20 01:15PM  
Jul-06-20 12:13PM  
Jun-22-20 04:35PM  
Jun-16-20 08:27PM  
Jun-15-20 04:01PM  
09:47AM  
Jun-12-20 02:30AM  
Jun-10-20 11:30AM  
Jun-08-20 08:00AM  
May-29-20 09:00AM  
May-28-20 12:00PM  
May-25-20 12:00PM  
May-14-20 09:24AM  
08:00AM  
May-09-20 08:22PM  
May-06-20 03:32PM  
07:00AM  
May-05-20 02:06PM  
Apr-28-20 09:00AM  
Apr-24-20 12:00PM  
Apr-06-20 07:00AM  
Mar-24-20 08:58AM  
Mar-16-20 12:00PM  
Mar-10-20 04:12PM  
03:00PM  
Mar-06-20 01:00PM  
Feb-26-20 09:00AM  
Feb-19-20 10:35AM  
Jan-09-20 02:50PM  
Jan-06-20 12:34PM  
Dec-27-19 02:19PM  
Dec-16-19 06:00AM  
Dec-13-19 04:05PM  
Dec-10-19 09:05PM  
Dec-09-19 04:18PM  
10:00AM  
Dec-02-19 11:00AM  
Nov-29-19 12:15PM  
Nov-25-19 12:43PM  
Nov-13-19 09:00AM  
Nov-07-19 10:34PM  
Nov-06-19 11:35AM  
09:00AM  
06:48AM  
Oct-31-19 10:00AM  
Oct-14-19 08:06AM  
Oct-10-19 07:00AM  
Oct-04-19 08:52AM  
Oct-01-19 07:00AM  
Sep-26-19 12:00PM  
Sep-24-19 07:00AM  
Sep-23-19 07:17PM  
Aug-21-19 09:00AM  
Aug-07-19 04:05PM  
Jul-25-19 01:39PM  
Jun-13-19 02:57PM  
Jun-12-19 09:00AM  
Jun-03-19 09:00AM  
May-31-19 11:00AM  
May-23-19 10:28AM  
May-20-19 07:00AM  
May-16-19 09:00AM  
May-08-19 04:15PM  
Apr-19-19 08:00AM  
Apr-10-19 07:01PM  
Mar-14-19 05:24PM  
Mar-06-19 02:35PM  
Mar-04-19 07:00AM  
Feb-25-19 09:02AM  
Feb-22-19 01:24PM  
Feb-20-19 07:00AM  
Feb-12-19 08:52AM  
Feb-08-19 10:05AM  
10:03AM  
Feb-05-19 09:17AM  
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLDSMITH MARK ADirectorMar 04Option Exercise0.0014,987014,987Mar 08 05:44 PM
Reeve EmmaChief Financial OfficerFeb 22Option Exercise8.046,26050,3306,260Feb 23 05:58 PM
Reeve EmmaChief Financial OfficerFeb 22Sale37.606,260235,3730Feb 23 05:58 PM
Reeve EmmaChief Financial OfficerFeb 19Option Exercise8.044,01032,2404,010Feb 23 05:58 PM
Reeve EmmaChief Financial OfficerFeb 19Sale37.714,010151,2180Feb 23 05:58 PM
Reeve EmmaChief Financial OfficerFeb 18Option Exercise8.041,1008,8441,100Feb 19 04:17 PM
Reeve EmmaChief Financial OfficerFeb 18Sale37.581,10041,3430Feb 19 04:17 PM
Reeve EmmaChief Financial OfficerFeb 17Option Exercise8.044103,296410Feb 19 04:17 PM
Reeve EmmaChief Financial OfficerFeb 17Sale37.5641015,3980Feb 19 04:17 PM
COLUMN GROUP L P10% OwnerFeb 17Sale36.9510,000369,50399,155Feb 19 05:31 PM
COLUMN GROUP L P10% OwnerFeb 17Sale36.9510,000369,50399,155Feb 19 05:32 PM
Valentine KarenSee RemarksJan 19Option Exercise11.5017,203197,83417,203Jan 20 05:56 PM
Valentine KarenSee RemarksJan 19Sale33.9717,203584,4630Jan 20 05:56 PM
Reeve EmmaChief Financial OfficerDec 21Option Exercise6.815,72038,9755,720Dec 22 04:53 PM
GOLDSMITH MARK ADirectorDec 21Sale35.024,020140,769139,043Dec 28 04:02 PM
Reeve EmmaChief Financial OfficerDec 21Sale35.115,720200,8050Dec 22 04:53 PM
Reeve EmmaChief Financial OfficerJun 08Option Exercise7.605894,476589Jun 10 06:50 PM
Reeve EmmaChief Financial OfficerJun 08Sale37.5558922,1180Jun 10 06:50 PM
Raythatha JigarSee RemarksMay 12Option Exercise5.519,20950,74224,170May 13 06:25 PM
GOLDSMITH MARK ADirectorMay 12Option Exercise4.124,22517,399147,288May 13 06:29 PM
Senderowicz AdrianChief Medical OfficerMay 12Option Exercise5.519,35751,55725,241May 13 06:30 PM
Audia James EDirectorMay 12Sale50.106,100305,62225,434May 13 06:30 PM
Senderowicz AdrianChief Medical OfficerMay 12Sale50.189,357469,48815,884May 13 06:30 PM
GOLDSMITH MARK ADirectorMay 12Sale50.054,225211,474143,063May 13 06:29 PM
Raythatha JigarSee RemarksMay 12Sale50.179,209461,98114,961May 13 06:25 PM
Reeve EmmaChief Financial OfficerMay 11Option Exercise8.9216,062143,26916,062May 12 09:41 PM
Raythatha JigarSee RemarksMay 11Option Exercise5.512614314,987May 13 06:25 PM
GOLDSMITH MARK ADirectorMay 11Option Exercise1.55100155143,163May 13 06:29 PM
GOLDSMITH MARK ADirectorMay 11Sale50.001005,000143,063May 13 06:29 PM
Raythatha JigarSee RemarksMay 11Sale50.00261,30014,961May 13 06:25 PM
Reeve EmmaChief Financial OfficerMay 11Sale49.5316,062795,6230May 12 09:41 PM
Reeve EmmaChief Financial OfficerMay 08Option Exercise9.8512,741125,46712,741May 12 09:41 PM
Reeve EmmaChief Financial OfficerMay 08Sale49.5312,741631,0550May 12 09:41 PM
GOLDSMITH MARK ADirectorMay 06Option Exercise4.2611,46348,825154,526May 07 04:25 PM
Valentine KarenSee RemarksMay 06Option Exercise10.9612,566137,74912,566May 07 04:34 PM
Trojer PatrickChief Scientific OfficerMay 06Option Exercise7.0410,00070,38510,000May 07 04:39 PM
Valentine KarenSee RemarksMay 06Sale40.1012,566503,8970May 07 04:34 PM
Trojer PatrickChief Scientific OfficerMay 06Sale45.1610,000451,5530May 07 04:39 PM
Audia James EDirectorMay 06Sale45.157,500338,60031,534May 07 04:28 PM
GOLDSMITH MARK ADirectorMay 06Sale45.0611,463516,545143,063May 07 04:25 PM
GOLDSMITH MARK ADirectorMay 05Option Exercise3.503,14511,006146,208May 07 04:25 PM
Valentine KarenSee RemarksMay 05Option Exercise11.504,74454,5564,744May 07 04:34 PM
Valentine KarenSee RemarksMay 05Sale40.014,744189,8170May 07 04:34 PM
GOLDSMITH MARK ADirectorMay 05Sale40.013,145125,824143,063May 07 04:25 PM
GOLDSMITH MARK ADirectorApr 27Option Exercise1.55400620143,463Apr 29 08:20 PM
Valentine KarenSee RemarksApr 27Option Exercise11.504004,600400Apr 29 08:03 PM
GOLDSMITH MARK ADirectorApr 27Sale40.1240016,049143,063Apr 29 08:20 PM
Valentine KarenSee RemarksApr 27Sale40.1340016,0520Apr 29 08:03 PM
Valentine KarenSee RemarksApr 20Option Exercise11.507899,074789Apr 22 08:17 PM
Valentine KarenSee RemarksApr 20Sale33.6578926,5500Apr 22 08:17 PM